不适合移植的大 B 细胞淋巴瘤二线使用 axicabtagene ciloleucel：ALYCANTE 最终分析
Second-line axicabtagene ciloleucel in large B-cell lymphoma ineligible for transplantation: ALYCANTE final analysis.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
Talicabtagene Autoleucel：首次获批
英文原题：Talicabtagene Autoleucel: First Approval.
查看英文原题
Talicabtagene Autoleucel: First Approval.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
Talicabtagene autoleucel（NexCAR19）是一种正在由印度理工学院孟买分校（IIT-B）和 Immunoadoptive Cell Therapy（ImmunoACT）开发的嵌合抗原受体（CAR）T 细胞疗法，用于治疗复发/难治性 B 细胞恶性肿瘤。该疗法采用患者自体 T 细胞，经改造表达靶向 B 细胞的人源化抗 CD19 CAR。在一项 I 期和一项 II 期试验汇总结果中，复发/难治性 B 细胞恶性肿瘤患者单次静脉给予 talicabtagene autoleucel 后缓解率较高。2023 年 10 月 13 日，印度批准该疗法用于复发/难治性 B 细胞淋巴瘤及复发/难治性 B 细胞急性淋巴细胞白血病。本文总结了 talicabtagene autoleucel 的研发里程碑，并介绍其首次获批用于上述疾病的历程。
展开英文摘要原文
Talicabtagene autoleucel (NexCAR19 ) is a chimeric antigen receptor (CAR) T-cell therapy being developed by the Indian Institute of Technology, Bombay (IIT-B) and Immunoadoptive Cell Therapy (ImmunoACT) for the treatment of relapsed/refractory B-cell malignancies. Talicabtagene autoleucel contains autologous T cells from the patient, which have been modified to express a humanized anti-CD19 CAR that targets B cells.
A single intravenous dose of talicabtagene autoleucel was associated with high response rates in pooled results from a phase I and phase II trial in patients with relapsed/refractory B-cell malignancies. Talicabtagene autoleucel was approved in India for the treatment of relapsed/refractory B-cell lymphomas and relapsed/refractory B-cell acute lymphoblastic leukaemia on 13 October 2023.
This article summarizes the milestones in the development of talicabtagene autoleucel leading to this first approval for relapsed/refractory B-cell lymphomas and relapsed/refractory B-cell acute lymphoblastic leukaemia.
论文信息
- 作者
- Nie T
- 单位
- Springer Nature, Mairangi Bay, Private Bag 65901, Auckland, 0754, New Zealand. mdt@adis.com.Iran
- 文献类型
- 综述
- 期刊
- Molecular diagnosis & therapy2024 Jul
- 原文标识
- PubMed 38780683 · DOI 10.1007/s40291-024-00719-9